G. Requena

First name
G.
Last name
Requena
Czira, A., Requena, G., Banks, V., Wood, R., Tritton, T., Castillo, C. M., et al. (2023). Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β(2)-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England. Int J Chron Obstruct Pulmon Dis, 18, 643-659. http://doi.org/10.2147/copd.s405498
View
Requena, G., Banks, V., Czira, A., Wood, R., Tritton, T., Wild, R., et al. (2023). Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England. Int J Chron Obstruct Pulmon Dis, 18, 231-245. http://doi.org/10.2147/copd.s389281
View
Czira, A., Banks, V., Requena, G., Wood, R., Tritton, T., Wild, R., et al. (2022). Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England. Bmj Open Respir Res, 9. http://doi.org/10.1136/bmjresp-2022-001243
View
Requena, G., Banks, V., Czira, A., Wood, R., Tritton, T., Wild, R., et al. (2022). Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England. Int J Chron Obstruct Pulmon Dis, 17, 1781-1795. http://doi.org/10.2147/copd.s365480
View
Abbing-Karahagopian, V., Huerta, C., Souverein, P. C., de Abajo, F., Leufkens, H. G., Slattery, J., et al. (2014). Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. Eur J Clin Pharmacol. http://doi.org/10.1007/s00228-014-1676-z
View
Ruigomez, A., Brauer, R., Rodriguez, L. A., Huerta, C., Requena, G., Gil, M., et al. (2014). Ascertainment of acute liver injury in two European primary care databases. Eur J Clin Pharmacol. http://doi.org/10.1007/s00228-014-1721-y
View
Brauer, R., Ruigomez, A., Downey, G., Bate, A., Rodriguez, L. A. G., Huerta, C., et al. (2016). Prevalence of antibiotic use: a comparison across various European health care data sources. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3831
View
Requena, G., Huerta, C., Gardarsdottir, H., Logie, J., Gonzalez-Gonzalez, R., Abbing-Karahagopian, V., et al. (2016). Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related drugs): a methodological approach to assess consistencies across databases from the PROTECT-EU project. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3816
View
Huerta, C., Abbing-Karahagopian, V., Requena, G., Oliva, B., Alvarez, Y., Gardarsdottir, H., et al. (2016). Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3825
View
Requena, G., Wolf, A., Williams, R., Dedman, D., Quint, J. K., Murray-Thomas, T., & Pimenta, J. M. (2020). Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real-world trials. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5188
View